▲ 0.82%
prev close
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Congressional Trades
7
All tracked trades
Members Trading
3
Unique members
Net Activity
-1
3 buys · 4 sells
Members Who Traded This Stock
7 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-10-30 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 243d ago | — | |
| 2025-09-25 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 273d ago | — | |
| 2025-07-22 | NVSNovartis AG Common Stock | Sell | $1,001 - $15,000 | 343d ago | — | |
| 2025-06-11 | NVSNovartis AG Common Stock | Buy | $1,001 - $15,000 | 343d ago | — | |
| 2025-03-24 | NVSNovartis AG Common Stock | Sell | $100,001 - $250,000 | 455d ago | — | |
| 2023-07-10 | NVSNovartis AG Common Stock | Sell | $50,001 - $100,000 | 1074d ago | — | |
| 2023-03-31 | NVSNovartis AG Common Stock | Buy | $50,001 - $100,000 | 1192d ago | — |
2025-10-30
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
243d ago
2025-09-25
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
273d ago
2025-07-22
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
343d ago
2025-06-11
Lisa McClain
NVS
Amount
$1,001 - $15,000
Filed
343d ago
2025-03-24
George Whitesides
NVS
Amount
$100,001 - $250,000
Filed
455d ago
2023-07-10
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
1074d ago
2023-03-31
Daniel Goldman
NVS
Amount
$50,001 - $100,000
Filed
1192d ago
Recent News
Powered by Polygon.io
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating
Global Cancer Biomarkers Market to Reach $37.8 Billion by 2035 as Precision Oncology Adoption Accelerates - Trends and Forecasts Till 2035
Antiparasitic Drugs Market Report Released — Examines Antimalarials, Anthelmintics, Antiprotozoals, Ectoparasiticides, and Neglected Tropical Disease Therapies
Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider
Trade Timeline
Congressional activity, newest first
Lisa McClain
2025-10-30 · Purchase
$1,001 - $15,000
Lisa McClain
2025-09-25 · Sale
$1,001 - $15,000
Lisa McClain
2025-07-22 · Sale
$1,001 - $15,000
Lisa McClain
2025-06-11 · Purchase
$1,001 - $15,000
George Whitesides
2025-03-24 · Sale
$100,001 - $250,000
Daniel Goldman
2023-07-10 · Sale
$50,001 - $100,000
Daniel Goldman
2023-03-31 · Purchase
$50,001 - $100,000